Sanger Heart & Vascular Institute Presents:
The Dowd Foundation Center Cardio-Oncology Symposium
Saturday, October 12, 2024 | 8:30 AM - 4 PM
As the landscape of cancer therapeutics rapidly evolves, overall cancer survival is improving at an unprecedented pace. However, patients are now living long enough for cardiovascular complications to emerge as an alternate cause of morbidity and mortality. In addition, life-saving cancer treatments such as chemotherapy, radiation therapy, and targeted therapy, may be stopped prematurely due to adverse effects on the cardiovascular system. This has led to the rapid expansion of cardio-oncology, a collaborative field that strives to maximize the benefit of cancer treatments while minimizing cardiotoxicity to improve outcomes and quality of life in cancer patients with cardiovascular disease.
Join us in person or virtually for a clinically oriented symposium focusing on challenging cases in cardio-oncology . This will be a case-based, “beyond the basics” curriculum focusing on the difficult clinical dilemmas that arise in the care of this complex patient population, with an emphasis on the concept of permissive cardiotoxicity. The symposium will feature case presentations, interdisciplinary panel discussions, and interactive Q&A's with experts in the field of cardio-oncology, and will cover high-yield topics such as amyloidosis, immunotherapy, and cardiac critical care while also providing opportunities for networking and collaboration among participants. This conference is designed for all healthcare professionals that are involved in the care of cardio-oncology patients or have an interest in the field.
Topics
Prevention of Cardiac Events After Cardiotoxic Treatments – More Than an Ounce
Cardiac Optimization Prior to CAR-T and Stem Cell Transplant – Moving Beyond Ejection Fraction
Permissive Cardiotoxicity in Breast Cancer Therapies – Straining for Clarity
Complex Cases of Immunotherapy Cardiotoxicity – When Seeing Is Not Believing
Cardiac Considerations in Chronic Targeted Therapies – Hindsight Is 50/50
Cardiac Amyloidosis 201 – Not for the Faint of Heart